title: Pre- and postsynaptic actions of a partial D2 receptor agonist in reserpinized young rats: longevity of agonistic effects.
abstract: Partial D2 receptor agonists (e.g., terguride, preclamol, and aripiprazole) have antagonist-like effects at normosensitive D2 postsynaptic receptors and synthesis modulating autoreceptors. In reserpine-pretreated adult and young rats, however, partial D2 agonists function like high efficacy agonists at D2 postsynaptic receptors and autoreceptors (i.e., terguride increases locomotor activity and decreases dopamine synthesis). The purpose of the present study was to examine the time-course of these pharmacological effects. In all experiments, preweanling rats were given daily injections of reserpine (1 mg/kg, i.p.) or vehicle on postnatal day (PD) 16-PD 20. In the dopamine synthesis experiments, the ability of terguride (0.8 mg/kg) to reduce striatal DOPA accumulation (in NSD-1015 treated rats) was assessed either 5 h or 1, 2, 4, or 8 days (Experiment 1) or 4, 8, 12, 16, 20, or 24 days (Experiment 2) after reserpine pretreatment. In the behavioral experiments, locomotor activity of vehicle or terguride (0.8 mg/kg, i.p.) treated rats was assessed 5 h or 1, 2, 4, or 8 days after the 5-day reserpine regimen. Results from the dopamine synthesis experiments showed that terguride caused agonist-like effects (i.e., decreased DOPA accumulation) at only the 5 h and 1 day time points, although terguride did not induce its normal antagonist-like effects even 20 days after reserpine pretreatment. In the behavioral experiments, terguride stimulated locomotor activity for only the initial 2 days after reserpine pretreatment. The results of the present study show that the agonistic effects of terguride at pre- and postsynaptic receptors are short-lived, but terguride may not exhibit normal antagonistic effects, at least at synthesis modulating autoreceptors, until long after conclusion of reserpine pretreatment.
authors.affiliation: Department of Psychology, California State University, San Bernardino, CA 92407, USA.
authors.forename: Cristal M
authors.initials: CM
authors.lastname: Farley
authors.forename: Shelley A
authors.initials: SA
authors.lastname: Baella
authors.forename: Jennifer J
authors.initials: JJ
authors.lastname: Wacan
authors.forename: Cynthia A
authors.initials: CA
authors.lastname: Crawford
authors.forename: Sanders A
authors.initials: SA
authors.lastname: McDougall
mesh_terms: D000367:Age Factors; D000818:Animals; D000831:Animals, Newborn; D017660:Autoreceptors / Q000502:physiology*; D001522:Behavior, Animal / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003342:Corpus Striatum / Q000187:drug effects; D047630:Depsipeptides; D004295:Dihydroxyphenylalanine / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D015259:Dopamine Agents / Q000494:pharmacology; D018491:Dopamine Agonists / Q000494:pharmacology*; D004347:Drug Interactions; D009043:Motor Activity / Q000187:drug effects; D010455:Peptides / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017448:Receptors, Dopamine D2 / Q000502:physiology*; D013997:Time Factors
chemical_list: D017660:Autoreceptors; D047630:Depsipeptides; D015259:Dopamine Agents; D018491:Dopamine Agonists; D010455:Peptides; D017448:Receptors, Dopamine D2; C081425:respirantin; D004295:Dihydroxyphenylalanine; D004298:Dopamine